P.O Box 1450

COMMISSIONER FOR PATENTS Alexandria, VA 22313-1450



Docket No.: 200.1134CON Date: September 2, 2004

In re application of:

Benjamin OSHLACK, et al.

Serial No.:

10/747,865

Filed:

December 29, 2003

For:

CONTROLLED-RELEASE COMPOSITIONS CONTAINING OPIOID AGONIST AND

**ANTAGONIST** 

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

- Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been [] established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 C.F.R. 1.9 and [] 1.27 is enclosed.
- No fee for additional claims is required.
- A filing fee for additional claims calculated as shown below, is required: []

FOR:	(Col. 1)	(Col. 2) HIGHEST	<del>-</del>	SMAI		- OR	LARGE ENTITY
TOK.	AFTER	PREVIOUSLY	PRESENT	10111		<u> </u>	TIGHT TEB
	AMENDMENT	PAID FOR	EXTRA				
TOTAL CLAIMS	* Minu	ıs 20** =		x \$	9 \$		x \$ 18 \$
INDEP. CLAIMS	* Minu	ıs 3*** =	0	x \$ 4	2 \$		x \$ 84   \$
[ ] FIRST PRES	SENTATION OF	MULTIPLE DE	EP. CLAIM	+ \$14	0 \$		+ \$280 \$
<del></del>	· · · · · · · · · · · · · · · · · · ·						

TOTAL: \$

TOTAL:

If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X] Also transmitted herewith are:

[] Petition for extension under 37 C.F.R. 1.136 (in duplicate)

[X] Other: PTO form 1449 (24 pages).

references cited and Exhibit A

- [] Check(s) in the amount of \$. 00 is/are attached to cover:
  - [] Filing fee for additional claims under 37 C.F.R. 1.16
  - [ ] Petition fee for extension under 37 C.F.R. 1.136
  - [ ] Other:
- The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552.
  - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.
  - Any patent application processing fees under 37 C.F.R. 1.17. [X]

[X] Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

1.136.

Robert J. Paradiso, Reg No. 41,240 DAVIDSON, DAVIOSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450". on September 2, 2004.

Elizabeth Pietrowski

BEST AVAILABLE COPY

New York, New York 10018



## UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be determined; Art Unit: 1614

Re: Application of:

Benjamin OSHLACK et al.

Serial No.:

10/747,865

Filed:

December 29, 2003

For:

CONTROLLED-RELEASE COMPOSITIONS

CONTAINING OPIOID AGONIST AND

**ANTAGONIST** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 September 2, 2004

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (24 sheets) for consideration by the Examiner in connection with the examination of the above-identified patent application.

Pursuant to 37 C.F.R. § 1.98 (a), the foreign patent documents listed on sheet 21 of the attached Form PTO-1449, which were not cited in the parent application, references UJ and UK, are enclosed. In accordance with the provisions of 37 C.F.R. § 1.98 (d), the references listed on pages 1-24 which were previously submitted in the parent application, U.S. Serial No. 09/781,076, are not enclosed. If it is determined that any of the listed references were not submitted in the parent application or presently enclosed, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

Applicants also respectfully advise the Examiner of the following U.S. Patents and copending U.S. Patent Applications which are commonly assigned to the owners of the instant application:

U.S. Application Serial No. 10/694,559, entitled "Opioid Agonist/Antagonist Combinations", filed October 27, 2003, which is a continuation of U.S. Application Serial No. 10/244,783, entitled "Opioid Agonist/Antagonist Combinations", filed September 16, 2002, now U.S. Patent No. 6,696,066, issued February 24, 2004, which is a continuation of U.S. Application Serial No. 09/815,167, entitled "Opioid Agonist/Antagonist Combinations", filed March 22, 2001, now U.S. Patent No. 6,475,494, issued November 5, 2002, which is a continuation of U.S. Application Serial No. 09/218,662, entitled "Opioid Agonist/Antagonist Combinations", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued August 21, 2001;

U.S. Application Serial No. 10/389,238, entitled "Naltrexone Hydrochloride Compositions", filed March 14, 2003;

U.S. Application Serial No. 10/700,906, entitled "Tamper Resistant Oral Opioid Agonist Formulations", filed October 30, 2003 and U.S. Application Serial Nos. 10/700,893, 10/700,861, 10/701,041 and 10/689,866, entitled "Tamper Resistant Oral Opioid Agonist Formulations", filed November 4, 2003, which are continuations of U.S. Application Serial No. 09/781,081, entitled "Tamper Resistant Oral Opioid Agonist Formulations", filed February 8, 2001, now U.S. Patent No. 6,696,088, issued February 24, 2004;

U.S. Application Serial No. 09/992,936, entitled "Opiod Agonist/Opioid Antagonist Acetaminophen Combination", filed November 5, 2001, which is a continuation of U.S. Application Serial No. 09/503,020 filed February 11, 2000 entitled "Opioid Agonist/Opioid Antagonist/Acetaminophen Combinations", now U.S. Patent No. 6,375,957, issued April 23, 2002, which is a continuation in part of U.S. Application Serial No. 09/218,662, "Opioid Agonist/Antagonist Combinations", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued August 21, 2001, listed as reference WG on the attached Form PTO-1449;

U.S. Application Serial No. 10/665,735, entitled "A Method of Preventing Abuse of Opioid Dosage Forms", filed September 18, 2003, which is a continuation of U.S. Application Serial No. 09/815,162, now U.S. Patent No. 6,627,635, issued September 30, 2003, listed as reference XI on the attached Form PTO-1449;

- U.S. Application Serial No. 10/827,623, entitled "Pharmaceutical Products", filed April 19, 2004;
- U.S. Application Serial No. 10/213,919, entitled "Opioid Agonist Formulations with Releasable and Sequestered Antagonist", filed August 6, 2002;
- U.S. Application Serial No. 10/214,408, entitled "Sequestered Antagonist Formulations", filed August 6, 2002; and
- U.S. Application Serial No. 10/199,972, entitled "Pharmaceutical Combinations of Oxycodone and Naloxone", filed July 18, 2002.

Pursuant to 37 C.F.R. § 1.98 (a)(2)(iii), the Examiner's attention is directed to **Exhibit A**, attached herewith, which contains the following:

- (i) the claims of pending U.S. Application Serial No. 09/992,936, which has the same specification as U.S. Patent No. 6,375,957, listed as reference XE on the attached Form PTO-1449;
- (ii) the claims of pending U.S. Application Serial No. 10/665,735, which has the same specification as U.S. Patent No. 6,627,635, listed as reference XI on the attached Form PTO-1449;
- (iii) the claims of pending U.S. Application Serial Nos. 10/700,906, 10/700,893, 10/700,861, 10/701,041 and 10/689,866, which have the same specification as U.S. Patent No. 6,696,088, listed as reference XK on the attached Form PTO-1449;
- (iv) the claims of pending U.S. Application Serial No. 10/694,559, which has the same specification as U.S. Patent No. 6,696,066, listed as reference XL on the attached Form PTO-1449;

(v) the specifications and claims for pending U.S. Applications Serial Nos. 10/213,919, 10/214,408, 10/199,972, 10/827,623 and 10/389,238.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 (24 sheets) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97 (b), before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. In the event any additional fee is due or any overpayment made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said deficiency or credit overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Robert J. Paradisc

Reg. No. 41/240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14<sup>th</sup> Floor New York, New York 10018 (212) 736-1940

FORM PTO-1449 (REV. 7-80)

LIST OF PRIOR ART CIT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1134CON

SERIAL NO.: 10/747,865

(KEV. 1-00)	_	\$ ×		132		MILINI	MINU I	NAULI	WARK OFFICE	200.1134CON		10/141,000		
	LIST	OF PI	DEN <sup>3</sup> RIOR	ART (	CITED	BY A	PPLIC	ANT		APPLICANT(S): Benjamin OSHLACK 6	et al.			
	(Use s	everal s	heets i	f neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUMI	BER				DATE	NAME	CLASS	SUBCLASS	FILING DA	
	AA	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65		
	AB	3	1	3	3	11	3	2	05/12/64	Loeb, et al.	264	49		
	AC	3	1	7	3	8	7	6	03/16/65	Zobrist	252	137		
-	AD	3	2	7	6	5	8	6	10/04/66	Rosaen	210	90		
	AE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285		
	AF	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260		
	AG	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260		
	AH_	3	7	7	3	9	5_	5	11/73	Pachter et al.	424	260		
	Al	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260		
								FOR	EIGN PATENT D	OCUMENTS		<del>,</del>		
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	AJ	8	3	0	3	1	9	7_	9/83	wo	A61K	9/22		
	AK	9	0	0	4	9	6	5_	05/17/1990	wo	A61K	31/485	ļ	<u> </u>
	AL	9	4	0	6	4	2	6	3/94	wo	A61K	31/46	<u> </u>	
	AM	9	5	0_	3	8	0	4	2/95	wo	A61K	31/485	<u> </u>	
	AN	9	6	0	2	2	5	1	2/96	wo	A61K	31/485		
					01	THER P	RIOR A	ART (In	cluding Author, T	itle, Date, Pertinent Page	s, Etc.)			
_	AO	Foss Mor	s, J.F., e ohine",(	et al.Ab	stract, "I Chemot	Prevent her Pha	ion of A	кротоп (1998)	ohine- or Cisplati ; 42(4):287-91.	n- induced emesis in the	dog by combina	ation of Methylnaltre	xone and	
	AP				y of Or ); 52:16		ninister	ed Meth	nylnaltrexone in E	Decreasing Subjective Eff	ects After Intrav	venous Morphine",D	rug and Alcoh	ol
	AQ	Gan 1080		Opioid-	Sparing	Effects	of a Lo	ow-Dos	e Infusion of Nato	oxone in Patient-Administ	ered Morphine	Sulfate," Anesthesio	ology (1997), 8	37(5):1075
	AR				ow Dos				torphine Increase	Morphine's Antinociece	otive Potencey	and Attenuate Toler	ance/Depende	ence in
	AS	Yuai	n et al.,	"The S		d Effica			hylnaltrexone in I	Preventing Morphine-indu	uced Delay in O	ral-Cecal Transit Ti	me", Clinical T	rials and
	AT						ne and I	Naloxor	ne Interactions in	Opiate Dependent Volur	teers," Clin. Ph	ar. Ther. (1996), 60	:105-114.	
	AU	Wals	sh et al.	, "Effec	ts of Na	ltrexon	e on Re	sponse	to Intravenous C	Cocain, Hydromorphone a	and their Combi	nation in Humans,"	(1996).	
EXAMINER										DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not con-

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-144 (REV. 7-80)	9								COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIST	OF P	RIOR	ART	CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACK et	al.		· · · · · · · · · · · · · · · · · · ·	
	(Use s	several s	sheets	f neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614	_	
		·						U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	ВА	3	9	1	6	8	8	9	11/04/1975	Russell	128	145.8		
	ВВ	3	9	6_	5	2	5	6	06/22/1976	Leslie	424	22		
	вс	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260		
	BD_	4	1	7	6	1	8	6	11/79	Goldberg	424	260		
	BE 4 2 3 7 1 4 0 12									Dudzinski	424	260		
								FORE	EIGN PATENT D	OCUMENTS				
		DOC	UMEN	TNUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	NC
													YES	NO
	BF	9	7	3	3	5	6	6	9/97	wo	A61K	9/20		
	BG	9	8	3	5	6	7	9	8/98	wo	A61K	31/485		
	вн	9	9	3	2	1	2	0	7/99	wo	A61K	31/485		
	ВІ	0	0	0	1	3	7	7	01/13/2000	wo	A61K	31/00		
	ВЈ	8	7	0	1	2	8	2	03/12/1987	wo	A61K	31/485		
					01	HER P	RIOR A	ART (Inc	duding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	ВК	Chih	-Cheng	Chien,	et al., "	Sigma	Antagor	nists Po	tentiate Opioid A	nalgesia in Rats", Neuroso	cience Letters 1	190 (1995), 137-139		
	BL	Crain Antir	n et al., nocicep	"Ultra-L tive Pot	ow Cor	ncentrat d Atten	ions of uating	Naloxo Toleran	ne Selectively Ar ce/Dependence	atagonize Excitory Effects of During Chronic Cotreatme	of Morphine on nt," Proc. Natl.	Sensory Neurons, Acad. Sci. USA (19	Thereby Increas 95) 92:10540-10	ing Its 1544.
	BN	Hans	son, An	algesic,	, Antipyı	etic an	d Anti-Ir	nflamma	atory Drugs in Re	emington's Science and Pr	actice of Pharn	nacy (1995), 2:1207		_
	во	Talw	in NX,	Physicia	an's De	sk Refe	rence 4	8 <sup>th</sup> Ed.	(1994) Montvale	, NJ 2120-2121.				
	ВР	Foss	et al.,	"Dose r	elated A	ntagon	ism of t	he Eme	etic Effect of Mor	phine by Methylnaltrexone	in Dogs",J. Cli	n Pharmacol (1993)	, 33:747-751	
	BQ	Holn	nes et a	al., "Inhil	biting S	oinal Dy	/norphir	n A Con	nponent Enhance	es Intrathecal Morphine An	tinocicption in I	Mice", Anesth. Anal	g. (1993), 77:11	66-73.
	BR	Miak 274.	owski	et al., "Ir	hibition	of Spir	nal Opio	oid Anal	gesia by Supras	oinal Administration of Sele	ective Opioid A	ntagonists", Brain R	esearch (1992),	30:263-
EXAMINER										DATE CONSIDERED				
*EXAMINER: Init						ot citatio	on is in o	conform	ance with MPEP	1 609; Draw line through cit	ation if not in c	onformance and no	t considered. In	clude

FORM PTO-1449 (REV. 7-80)									F COMMERCE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIST	OF P	RIOR	ART C	SITED	BY A	.PPLI(	CANT		APPLICANT(S): Benjamin OSHLACK e	et al.			
	(Use s	several s	sheets i	if necess	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	.S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUME	3ER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	CA	4	2_	8	5	9	8	7	08/25/1981	Ayer, et al.	427	3		
	СВ	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56		
	СС	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260		
	CD	4	4	4	3	4	2	8	04/17/1984	Oshlack et al.	424	22		
	CE	4	4	5	1	4	7	0	5/84	Ganti	424	260		
	CF	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260		
	CG	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260		
	L	<u>.l</u>	<u> </u>						EIGN PATENT D	<del>*</del>	<u></u>			
		DOC	UMEN	T NUME	3ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	 ON
	i												YES	NO
	СН	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
	CI	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
	CJ	0	1	3	7	7	8	5	05/31/2001	WO (A2)	A61K			
	СК	0	1	5	2	8	5	1	07/26/2001	WO (A1)	A61K	31/485		
	CL	0	1	8	5	2	5	7	11/15/2001	WO (A2)	A61P			
					01	THER P	RIOR /	ART (In	cluding Author, T	itle, Date, Pertinent Page	s, Etc.)			
	СМ	Weir 274.		al., "Bu						altrexone in Non-Depende		rug and Alcohol De	pendence (1992)	), 30:263-
	CN	Cap	pel et al	I., "Enha	anceme	nt of Na	aloxone	Induce	ed Analgesia by P	retreatment with Morphin	e" Pharma. Bio	ch. & Behav. (1989)	), 34:425-427.	
	со	Vacc	arino e	t al.,"An	nalgesia	Produc	ced by I	Normal	Doses of Opioid	Antagonists Alone and in	Combination w	ith Morphine", Pain	(1989), 36:103-1	109.
	СР			t al., "Na e," Drug					armacodynamic a	and Pharmacokinetic Prop	erties and Ther	apeutic Efficacy in t	he Management	of Opioid
	cQ	Suns 4:35		t al., "Ar	nalgesio	: Efficad	cy of Pe	intazoci	ine Versus a Pen	ntazocine-Naloxone Comb	ination Followin	ng Oral Administrati	on," Clin. J. Pain	(1988),
	CR	Wan	g et al.,	, "Cross	over an	d Paral	lel Stud	y of Or	al Analgesics," J.	Clin. Pharmacol (1981),	21:162-168.			
	cs	Tran	slation	of Germ	nan pate	ent appl	lication	DE 43	25 465					
EXAMINER									. 7	DATE CONSIDERED				
*EXAMINER: Initia						ot citatic	n is in (	conform	nance with MPEP	P 609; Draw line through c	itation if not in o	conformance and no	ot considered. In	ıclude

FORM PTO-1449 (REV. 7-80)		-							COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIST	OF P	RIOR	ART (	CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACK et	al			
	(Use s	several s	sheets i	f neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
		,						U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	DA	4	5	7	3_	9	9	5_	3/86	Chen et al.	604	896		
	DB	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
	DC	4	6	0	8	3	7	6	8/86	Pastemak	514	282		
	DD	4	6	6	1	4	3	2	4/87	Lewis et al.	514	282		
	DE 4 7 1 9 2 1 5									Goldberg	514	282		
										Portoghese et al.	546	45		
	DF 4 7 3 0 0 4 8 3/8 DG 4 7 6 0 0 6 9 7/8									Rzeszotarski et al.	514	282		
								FORE	EIGN PATENT D	OCUMENTS				
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	NO
	DН	0	1_	9	3	8	5	2	12/31/2001	WO (A2)	A61K	31/00		
	DI	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		
	DJ	0_	6	4	7	4	4	8	4/95	EP	A61K	31/485	·	
	DK	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
	DL	0_	2	0	5	2	8	2	12/86	EP	A61K	9/22		1
					0	THER P	RIOR A	ART (Inc	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	DM	Alav Phar	rez-Fue m Pha	entes, e mcaol (	t al. "Eff (2001),	ectiven 53:120	ess of F I-1205.	Repeate	ed Administration	of a New Ora Naltrexone	Controlled-Rele	ease System in Mor	phine Analgesia	ı"; J.
	DN	Alva	rez-Fue	entes, e	t al., "Pr	eclinica	l Study	of an C	Oral Controlled Re	elease Naltrexone Comple	x in Mice"; J. P	harm Pharmacol (2	000), 52:659-66	3.
	DO	Arch	er, Syd	ney; "H	istorical	Perspe	ective o	n the Cl	hemistry and Dev	velopment of Naltrexone";	Naltrexone Res	earch Monograph2	8 (1980) p. 3-9.	
	DP	Baur	n et al.	, "The Ir	npact o	f the Ac	ldition o	f Nalox	one on thr Use a	nd Abuse of Pentazocine";	Public Health	Reports (1987) Vol.	102, No. 4 p. 4	26-429.
	DQ	Rapa	aka et a	al., "Disc	covery o	f Novel	Opioid	Medica	ations"; NIDA Res	search Monograph 147 (19	95) p. 55-83.			
	DR		m et al.							o of 1:20"; 5 <sup>th</sup> National Cor		thadone Treatment	(1973) Vol 2, p.	1342-
EXAMINER				-						DATE CONSIDERED			·	
*EXAMINER: Initia copy of this form v						ot citatio	n is in o	conform	nance with MPEP	609; Draw line through cit	tation if not in c	onformance and no	t considered. In	nclude

FORM PTO-1449 (REV. 7-80)									COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIST	OF PI	RIOR	ART (	CITED	BY A	PPLIC	ANT		APPLICANT(S): Benjamin OSHLACK et	al.			
	(Use s	several s	heets i	fneces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUMI	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	EA	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282		
	EB	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
	EC	4	8	0	3	2	0	8	2/89	Pasternak	514	282		
	ED	4	8	0	6	3	4	1	2/89	Chien et al.	424	448	-	
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464		
	EF	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381		
	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419		
	1_0	1 7							EIGN PATENT D		1 121	110		
				T NUM	DED			TON	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	)N
		000	OWEN	INOIN	DEIX				DAIL	COONIKI	CLAGG	OODOLAGO	YES	NO
		<u> </u>			т.			τ					120	
	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
	EI	0	3_	1	9	2	4	3	06/07/1989	EP (A1)	A61K	31/485		
	EJ	0_	3	1	9	2	4	3	11/07/1990	EP (B1)	A61K	31/485		
	EK	19	6	5	1	5_	5	1	6/98	DE	A61K	31/485		
	EL	29	7	1	9	7	0	4	2/97	DE	A61K	31/485	х	
					0	THER P	RIOR A	ART (In	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
	EM	Briso	oe et a	ıl., "Met	hoclocir	namox	: Time (	Course	of Changes in Al	fetnanil-Reinforced Rhesu	s Monkeys"; Ps	ychopharmacology	(2000) 148:393-	-399.
	EN	Abst	ract of	Bromm,	, et al., '	'A Sens	itive Me	ethod to	Evaluate Effects	of Analgesics in Man"; Me	eth and Find Ex	ptl Clin Pharmacol	5 (8) (1983) p. <u>5</u>	45-551.
	EO	Bulli	ngham	et al., "	Clinical	Pharam	ncokine	tics of N	larcotic Agonist-	Antagonist Drugs"; Clinical	Pharm (1983)	8: 332-343.		
	EP	Calir		al. "Eff						ethadone in a 1:10 Oral Co			nere (1974) Vol.	15; No. 6
	EQ	Caru	iso et a	I., "Meti	nadone	and Na	loxone	in Com	bination (Naldon	e®) for the Treatment if He	roin Addicts"; E	Bristol Laboratories,	pp.1336-1341F.	
	ER	T							996) May:51 (5)					
	ES	Ť T								ase Preparation"; Drug and	Alcohol Depe	ndence (1985) 16, <sub> </sub>	op.1-8.	
EXAMINER	•	•								DATE CONSIDERED				
*EXAMINER: Initia						ot citatio	n is in	conform	nance with MPEF	P 609; Draw line through ci	ation if not in c	onformance and no	t considered. In	clude

FORM PTO-1449 (REV. 7-80)									COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIS	T OF PI	RIOR	ART (	CITED	BY A	PPLIC	ANT		APPLICANT(S): Benjamin OSHLACK et	al.			
	(Use	several s	heets if	neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCU	IMENT I	NUMBI	ĒR				DATE	NAME	CLASS	SUBCLASS	FILING DATE	_
	FA	4	8	3_	4	9_	6	5_	05/30/7989	Martani et al.	424	488		
	FB	4	8	3	4	9	8_	4	05/30/1989	Goldie et al.	424	488		
	FC	4	8	3	4	9	8	5	05/30/1989	Elger et al.	424	488		
	FD	4	8	4	4	9	0	7	07/04/1989	Elger et al.	424	465		
	FE	4	8	4	4	9	0_	9	07/04/1989	Goldie et al.	424	480		
	FF	4	8	4	4	9	1	0	07/04/1989	Leslie et al.	424	494		
	FG	4	8	6	1	5	9	8	8/89	Oshlak et al.	424	468		
								FORE	EIGN PATENT D	OCUMENTS				
		DOCU	IMENT I	NUMBI	≣R				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	NO
	FH	4	3	2	5	4	6	5	2/95	DE	A61K	31/485		x
,	FI	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
	FJ	9	8	2	5	6	1	3	06/18/98	wo	A61K	31/485	abstract	
	FK	0	0_	3	8	6	4	9	07/06/00	wo	A61K	9/00	abstract	
		•			0	THER P	RIOR A	RT (Inc	cluding Author, T	itle, Date, Pertinent Pages	Etc.)			
	FL	Chiang	g et al., '	'Kinetio	s of a l	Valtrexo	ne Sus	tained-l	Release Prepara	tion"; Clin Pharmacol Thera	a (1984) Vol 36	No. 5, pp.704-708		
	FM	Come	r et al., "	Depot	Naltrex	one: Lo	ng-lasti	ng Anta	gonism of the Ef	fects Of Heroin un Human	s"; Psychophar	macology (2002) 15	59, pp.351-360.	
	FN	Crabtr	ee et al.	, "Revi	ew of N	altrexo	ne, a lo	ng-actin	g Opiate Antago	nist"; Clinical Pharmacy, V	ol. 3 (1984) pp.	273-280.		
	FO									nhance Morphine's Analge Pain 82 (1999)pp.1-11.	esic Potency an	d Attenuate Opioid	Tolerance/depe	endence
	FP									nhance Morphine's Analge Pain 84 (2000) pp.121-13		nd Attenuate Opioid	Tolerance/depe	endence
	FQ	Fink e	t al., <u>"</u> na	loxone	in Her	oin Dep	endeno	e"; Clin	Pharm and Ther	a. Vol 9, No. 5;pp.568-577				
	FR	Fishm	an et al.	, "Disp	osition	of Nalo	cone-7,	3-3H in I	Normal & Narcoti	c Dependent Men"; J. Pha	rm. And Exper.	Thera (1973)Vol 1	0 No. 2;pp.57 <u>5</u> -5	580.
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initia						ot citatio	n is in o	conform	ance with MPEP	609; Draw line through cit	ation if not in co	onformance and no	t considered. In	clude

FORM PTO-1449 (REV. 7-80)	}								COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	LIST	OF P	RIOR	ART (	CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACK	et al.			
	(Use	several	sheets i	if neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	CUMEN	T NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATI	
	GA	4	88	6	1	7	8	1	8/89	Goldberg	514	282		
	GB	4	8	6	7	9	8	5	09/19/1989	Heafield et al.	424	461		
	GC	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10		_
	GD	4	8	8	2	3	3	5	11/89	Sinclair	514	282		
	GE	4	8	8	9	6	6	0	12/89	Rzeszotarski et al.	514	282		
	GF	4	9	3	5_	4	2	8	6/90	Lewis	514	282		
	GG	4	9	4	0	5	8	7	07/10/1990	Jenkins et al.	424	480		
								FOR	EIGN PATENT D	OCUMENTS				
		DOC	CUMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	МО
	GH	00	1	5	8	4	7	7	8/16/01	wo	A61P		abstract	
		<del></del>			0	THER F	RIOR	ART (In	cluding Author, T	itle, Date, Pertinent Pag	es, Etc.)			
	GI	Fras		ert D., e						Treatment of Opiate Dep		cal Toxicology I (199	0) Vol 10, No. 2	2; pp.375-
	GJ	Fre	ye et al.	, "Effect	s of Tra	madol	and Tilio	dine/Na	loxone on Oral-C	aecal Transit & Pupillar	light Reflex'; A	zneim-Forsch/Drug	Res. 50(I)(2000	)pp. 24 <b>-</b> 30.
	GK	Fud	lala, et a	al., "Effe	cts of B	upreno	rphine a	asnd Na	loxone in Morphi	ine-Stabilized Opioid Add	dicts"; Drug and	Alcohol Dependenc	e 50 (1998) pp.	1-8.
	GL	Fud	ala et a	l., "Hum	nan Pha	rmacolo	ogy and	Abuse	Potential Of Nalr	mefene"; Clin Pharm and	Thera (1991) V	ol 49, 3, pp. 300-30	<b>3</b> .	
	GM	Gal	et al., "I	Prolong	ed Bloc	kade of	Opioid	Effect v	with Oral Nalmefe	ene"; Clin Pharm and Th	era (1986) pp. 5	37-542.		
	GN									reatment of Heroin Addi			nt (1995) Vol 12	, 1, pp. 35-
	GO	Gho	odse, et	al., "Op	ioid ana	algesics	and Na	arcotic A	Antagonists"; Side	e Effects of Drugs (2000	) Annual 23, chp	t 8 pp. 96-113.		
EXAMINER										DATE CONSIDERED				

FORM PTO-14 (REV. 7-80)	49		-						COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	IO.:	SERIAL NO.: 10/747,865		
	LIST	)F PR	IOR A	RT C	ITED 1	BY AF	PPLIC.	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	НА	4	2	0	0	0	9	8	04/29/1980	Ayer, et al.	128	260		
	НВ	4	9	7	0	0	7	5	11/13/1990	Oshlak	424	451		
	НС	4	9	8	7	1	3	6	01/22/1991	Kreek et al.	514	282		
	HD	4	9	9	Ó	3	4	1	02/05/1991	Goldie et al.	424	484		
	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497		
<u> </u>	HF	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282		
	HG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282		
	•	,					F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	rion
													YES	NO
	НН	00	1	8	5	1	5	0	11/15/01	wo	A61K	31/00		
					OTHE	R PRIC	OR AR	T (Incl	uding Author,	Γitle, Date, Pertinent P	ages, Etc.)			
	ні			iam, M			A New	Metho	od for Detoxifyi	ng Opoiod-Dependent	Patients"; J.	Substance Abuse	Treatment (19	99)
	HJ	Gold	d, et al	. "Rap	id Opic	oid De	toxifica	ation D	uring General A	Anesthesia"; Anesthesi	ology (1999)	Vol 91, No 6, pp.	1639-1647.	
	нк			l, et al. 1 277, 1					narmacology of	Short-Acting µu Opio	ids in Drug A	busers"; J. Pharm	and Exper Th	era
	HL	Gup	ta, et a	al., "M	orphine	e Com	bined v	vith Do	oxapram or Nale	oxone"; Anesthesia (19	974) Vol 29, j	эр. 33 <b>-</b> 39.		
	ні			al., "C lo II)(1					Development of	of Dependence during	Oral Therapy	with Tramadol";	Arzniem-Forso	ch/Drug
	HN		en et a 173-17		e effec	t of La	motrig	ine on	Naloxone-preci	pitated Opiate withdra	wal"; Drug a	nd Alcohol Depen	dence (1998)	Vol 52,
	НО			l., "A I 51-257		udy of	Dextro	ometho	orphan in Nalox	one-Precipitated Opiat	e Withdrawa	l"; European J. of	Pharm. (1996	) Vol
EXAMINER										DATE CONSIDER	ED			
*EXAMINER: considered. Inc										e with MPEP 609; Dra	w line throug	gh citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	10.:	SERIAL NO.: 10/747,865		
	LIST	OF PRI	OR A	RT C	ITED 1	BY AF	PLIC	ANT		APPLICANT(S): Benjamin OSHLAO	CK et al.			
	(U	lse seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003	·	GROUP: 1614		
					–			U.S.	PATENT DOC					
*EXAMINER INITIAL		DOG	CUME	ENT N	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	IA	5	0	9	1	1_	8	9	02/25/1992	Heafield et al.	424	457		
	IB	5	0	9	6	7	1	5	3/92	Sinclair	424	449		
	IG	5	1	0	2	8	8	7	4/92	Goldberg	514	282		
	ID	4	1	6	4	0	2	0	07/03/1979	Ayer, et al.	424	15		
	IE	5	1	4	9	5	3	8	9/92	Granger et al.	424	449		
	IF	5	2	1	5	7	5	0	06/01/1993	Krishnamurthy	424	488		
	IG	5	2	2	5	4	4	0	7/93	London et al.	514	535		
					<u> </u>	•	F	OREI	GN PATENT D	OCUMENTS	•			
		DOG	CUME	ENT N	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	IH	00	0	6	7	7	3	9	11/16/00	wo	A61K	31/00		
	•		•		ЭТНЕ	R PRIC	OR AR	T (Incl		litle, Date, Pertinent P	•	•		1
	IL			I., "Bu	prenor	phine,	Morph	ine an	d Naloxone Effe			aintenance in Hur	nans"; J. Phari	m and
	IK	Schi	ıh et a	1. <b>,</b> "On	set, Ma	agnituo	de and	Durati	on of Opioid Bl	ockade Produced by E	Buprenorphine	and Naltrexone i	n Humans";	
	IL	Stev	ens et	al., "N	onspec	ific Ex	citato	y Effe	cts of Morphine	: Reverse-Order Preci	pitated Withd	rawal and Dose-I	Oose Interaction	ns':
	IM		200	7 7 7 7 7	A 20	2		10 22 7		1.20	during Metha	done and Bupren	orphine Mainte	enance";
	IN			1					-171-		Clinical Psyc	h. (1992) Vol 12,	No 3, pp. 203	-209.
	Ю													
	IP	Stra	in et al	l., "Acı	ite Eff	ects of	Bupre	norphi	ne, hydromorph					
	IQ	Stra	in et al	l., "Eff	ects of	buprei				ne/naloxone tablets in	non-depender	nt opioid abusers"	; Psychopham	nacology
	IR	Stra	in et al	l., "Pre	cipitate	d Wit	hdrawa	ıl by P	entazocine in M	ethadone-Maintained	Volunteers";	J. Pharm and Exp	er Thera (1993	3) Vol
	IG 5 2 2 5 4 4 0  FOREIGN  DOCUMENT NUMBER  IH 00 0 6 7 7 3 9  OTHER PRIOR ART (Included of the second of the seco									Addiction": NIDA (19	997) 5 nages			
EXAMINER	1 10	1 141,	ot at.,	- Trainin	zxone.	74174	uagom	30 1110	apy for Freioni	DATE CONSIDER				
*EXAMINER: considered. Inc										e with MPEP 609; Dra	aw line throug	th citation if not i	n conformance	and not

FORM PTO-144 (REV. 7-80)	49								COMMERCE IARK OFFICE	ATTY. DOCKET N 200.1134CON	10::	SERIAL NO.: 10/747,865		
	LIST O						PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(Us	se sever	ral shee	ets if n	ecessar	ry)				FILING DATE: December 29, 2003	3	GROUP: 1614		
								U.S	. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	CUME	NT NI	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA'	
	JA	5	2	2	6	3	3	1	07/13/1993	Thompson et al.	73	865.9		
	JВ	5	2	3	6	7	1	4	8/93	Lee et al.	424	449		
	JC	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282		
	JD	5	2	6	6	3	3	1	11/30/1993	Oshlak et al.	424	468		
	JE	5	2	7	3	7	6	0	12/93	Oshlak et al.	424	486		
	JF	5	2	8	6	4	9	3	02/15/1994	Oshlak et al.	424	468		
	JG	5	3	1	6	7	5_	9	12/93	Rose et al.	424	10		
	<del></del>	<b></b>						FOREI	IGN PATENT D					
		DO	CUME	NT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
													YES	NO
	JH	00	0	5	1_	5	9	2	9/05/00	wo	A61K	31/14		
					OTHE	R PRIC	OR AR	tT (Inc	luding Author,	Title, Date, Pertinent P	ages, Etc.)			
	JI		bricht e -190	et al., "	Naltre	xone s	horten	ed opic	oid detoxificatio	on with buprenorphine'	"; Drug and A	Icohol Dependen	ce (1999) Vol :	56 pp.
	JK	Vac	carino	et al.,	"Enog	enous (	Opiate	s: 1999	9"; Peptides 21 (	(2000) pp. 1975-2034.				
	JL								antagonists at µ ol 77, pp. 1590-1	opioid receptor (MOR 1600.	ζ): possible ro	le of basal recepto	or signaling in	narcotic
	JM	Way	y et al.,	, "Resp	onsivi	ty to N	laloxor	ne duri	ng Morphine De	ependence"; Annals No	ew York Acad	demy of Sciences,	, pp. 252-261.	
	JN	Wei	inberg	et al., '	'Sublir	igual a	bsorpt	ion of	selected opioid	analgesics"; Clin Phan	m Thera (198	8) Vol 44, No 3, j	pp. <u>335-342.</u>	
	JO	Limi		ntinoci						SoRI 9409, a Nonpept one Physical Depender				
	JP				rug Tr	eatmer	nt for C	) Opi <u>oid</u>	Dependence"; A	Australian Prescriber (2	2001) Vol 24,	No 1, pp. 4-6.		
	JQ	Wrig	ight et a	al., "Ac	cute ph	nysical	depend	dence i		eated naloxone-precipi	•		dose of methac	done";
	JR									n infant rat is attenuate ) Vol 150, pp. 325-336		lministration if N	OS inhibitors l	but not
EXAMINER	_									DATE CONSIDER	ED			
*EXAMINER: I considered. Inc										e with MPEP 609; Dra	aw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	IO.:	SERIAL NO.: 10/747,865		
	LIST C	)F PRI	OR A	RT C	ITED :	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	ENT NI	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	KA	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282		
	КВ	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25		
	KC	5	3	2	4	3	5	1	06/28/1994	Oshlak et al.	106	153		
	KD	5	3	3	6	6	9	1	08/09/1994	Raffa et al.	514	629		
	KE	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279		
	KF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289		
	KG	5	3	5	6	4	6	7	10/18/1994	Oshlak et al.	106	153		
							F	OREI	ON PATENT D	OCUMENTS				
		DOC	CUME	NT NU	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	ΓΙΟΝ
													YES	NO
	КН	0	1	5	8	4	5	1	08/19/2001	WO (A1)	A61K	31/485		
				(	ЭТНЕ	R PRIC	R AR	T (Incl	uding Author, T	itle, Date, Pertinent P	ages, Etc.)			
	KI	Han relea	et al., ise and	"Muco i muco	oadhe adhesi	sive bu ve perf	ccal d	isks fo	r novel nalbuph ternational J. Pl	ine prodrug controlled narm (1999) Vol 177,	delivery; effe pp. 201-209.	ect of formulation	variable on dr	rug
	KJ	Han	dal et a	al., "Na	aloxon	e"; Anı	als of	Emerg	gency Medicine	(1983) Vol 12:7, pp. 4	138-445.			
	KK								co-administrati	on in opiate dependen	t patients stat	oilized on subling	ual buprenorph	hine";
	KL			al., "E l) Vol				ise for	nulation of nalo	xone on intestinal tran	nsit in volunte	ers taking codein	e"; Aliment Ph	narm
	KM									nd bromfenac in expe			andomized cro	ssover
	KN	Bud	d, Keit	th, "Cli	inical (	Jse of	Opioid	Antag	onists"; Baillier	e's Clinical Anesthesi	iology (1987)	Vol 1, No 4, pp.	993-1011.	
	ко	Crai	n et al.	., "Ultr	a-low	concen	tration	s of na	loxone selective	ely antagonize excitato				nereby
	KP									ic Agonist/Antagonist	Analgesic":	NIDA Research (	1979) pp. 99-1	05.
	кQ	Leel	ing et		isposit					in the rat, dog, and ma				
EXAMINER		•				_				DATE CONSIDER	ED			
*EXAMINER: 1 considered. Inc										e with MPEP 609; Dra	w line throug	h citation if not in	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	Ю.:	SERIAL NO.: 10/747,865		
	LIST	OF PRI	IOR A	RT CI	TED I	BY AF	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)   U.S. P.									FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	ENT NU	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	LA	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282		
	LB	5	3	7	6	6	6	2	12/94	Ockert	514	282		
	LC	3	5	4	1	0	0	5	11/17/1970	Strathmann, et al.	210	19		
	LD	5	4	1	1	7	4	5	05/02/1995	Oshlack et al.	424	456		
	LE	5	4	2	6	1	1	2	06/95	Zagon et al.	514	282		
	LF	3	5	4	1	0	0	6	11/17/1970	Bixler, et al.	210	23		
	LG	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35		
	·	<u> </u>					F	OREI	ON PATENT D	OCUMENTS		-		
		DOG	CUME	NT NU	JMBE	R		-	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	rion
													YES	NO
	LH	0	8	8	0	3	5	2	02/03/1998	EP (B1)	A61K	31/485		х
				(	ЭТНЕІ	R PRIC	R AR	T (Incl	uding Author,	litle, Date, Pertinent P	ages, Etc.)			
	LI									gimens with the combi	ibation bupre	norphine-naloxon	e tablet"; Drug	g and
	LJ									and naltrexone in rats'	";(1987) Vol	36, pp. 127-130.		
	1	Jasii	nski et	al., "T	he hun	nan ph							nd Exper Ther	a (1967)
	LM	Jone	es et al	., "Nalı	mefene	:block			enous morphine	challenge effects in op	oioid abusinh	humans"; Drug a	nd Alcohol	
	LN	Kan	of et a		nical C	harate	ristics	of Nal		ted Withdrawal in Hur	nan Opioid-E	Dependent Subject	ts"; J Pharma a	ınd
	LO	King	g et al.		rexone	Biotra	nsforn	nation	and Incidence o	f Subjective Side Effec	cts: A Prelimi	nary Study"; Alco	oholism: Clin a	and
	LP	Kog	an et a	ıl., "Est	timatio	n of th	e Syste	emic A	vailability and	Other Pharmacokinetic And Pharm (1977) V			Aan after Acut	e and
	LQ	1								oine-Abusing Heroin A			/ (1994) Vol 1	p 151.
	LR	1	ten et :							ne maintained patients				
	LS	Kur	land et	al., "N 663-67		ne and	the Na	rcotic	Abuser: A Cont	rolled Study of Partial	Blockade"; I	nter. J. of the Add	lictions (1974)	Vol 9,
EXAMINER	.I	1 140.	<u>ν, μμ. (</u>		<u>.                                    </u>					DATE CONSIDER	ED .		-	
*EXAMINER:					-					e with MPEP 609; Dra	w line throug	gh citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 200.1134CON	NO.:	SERIAL NO.: 10/747,865		
17.4	LIST C	)F PRI	IOR A	RT C	TED :	BY AF	PPLIC	ANT		APPLICANT(S): Benjamin OSHLA	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 200	)3	GROUP: 1614		
		-						U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	MA	5	4	6	0	8	2	6	10/24/1995	Merrill et al.	424	470		
	МВ	5	4	7	2	2	1	2	12/05/1995	Oshlack et al.	424	480		
	ME	5	4	7	2	0	4	3	12/95	Crain et al.	514	12		
	MD	5	4	7	4	5	7	7	12/26/1995	Sackler et al.	424	489		
	ME	5	4	8	4	3	6	2	1/96	Kitchell et al.	424	426		
	MF	5	5	8	0	2	2	7	03/19/1996	Oshlack et al.	424	489		
			•				F	OREI	GN PATENT D	OCUMENTS	_			
		DOG	CUME	NT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	MG													
	•				ОТНЕ	R PRIC	OR AR	T (Inc	luding Author,	Title, Date, Pertinent	Pages, Etc.)			
	МН	Lee 815								vents Tolerance and		Anesth Analg (19	97) Vol 84, pp	o.810-
	MN		-		nflueno p. 343-		aloxon	e on tl	ne Postoperative	Analgesic and Resp	iratory effects	of Buprenorphine	"; Eur. J. Clin	Pharm
	МЈ	Lev	ine et a	al., "Po	tentiat	ion of	Pentaz	ocine 2	Analgesia by Lo	w-dose Naloxone"; J	Clin Invest (1	988) Vol 82, pp. 1	574-1577.	
	MK				ombine . 1 <i>5</i> 7-1		oxone/i	Methad	lone Preparation	ns for Opiate Substit	ution Therapy"	; J. of Substance A	Abuse Treatme	ent
	ML								of a New Tilidir pp. 599-607.	ne/Naloxone Liquid I	Formulation Co	mpared to a Refe	rence Formula	tion";
	ММ				emonst 1 1 <i>5</i> 0, 1				to and Physical	Dependence on N-al	llynormorphine	(Nalorphine)";J.	Of Pharm and	Exper
	MN								xone combination	ons: the effects of the	ree dose ratios i	n morphine stabil	ized, opiate-de	ependent
	мо	Mer	ndelson	n et al.,		enoph	ine and			in Methadone Main	ntenance Patien	ts"; Society of Bi	ological Psych	iatry
	МР		t et al.,					xture f	or use in metha	done maintenance pr	ograms"; Clin	Pharm and Ther.	Vol 15, No 2.,	pp 156-
EXAMINER	•	-								DATE CONSIDE	RED			
*EXAMINER: considered. Inc										e with MPEP 609; D	raw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	Ю.:	SERIAL NO.: 10/747,865		
	LIST	)F PRI	IOR A	RT CI	TED I	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT NU	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	NA	5	5	0	2	0	5	8	3/96	Mayer et al.	514	289		
	NB	5	5	0	8	4	1	2	04/16/1996	Oshlack et al.	424	468		
	NC	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484		
	ND	5	5	1	2	5	7	8	4/96	Crain et al.	514	282		
	NE	5	5	1_1_	4	6_	8	0	5/96	Weber et al.	514	249		
							F	OREI	GN PATENT D	OCUMENTS				
		DOG	CUME	NT NU	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
													YES	NO
	NE													
				(	ЭТНЕ	R PRIC	R AR	T (Incl	uding Author, 7	itle, Date, Pertinent Pa	ages, Etc.)			
	NG		vatikai 141-94	et al.,						the Treatment of Hero		Clin. Pharm and	Thera, Vol 14,	No. 6,
	NH		vartika 0-1354		, "Nalo	xone-l	Methad	lone C	ombination for	he Treatment of Opiat	e Dependence	e"; Missouri Insti	tute of Psychia	ıtry, pp.
	NI	Alor		in Con						ffects of Kappa Opioio				
	NJ			al., "Bı . 484-4		rphine	and N	aloxon	e alone and in c	ombination in Opioid-	dependant Hi	umans"; Psychop	harmacology (	1988),
	NK			al., "Di ra (199						omorphone and Penta	zocine Effects	s in Human Volu	nteers"; J of Ph	arm and
	NJ			al., "Ef		f Subl	nguall	y give	n naloxone in O	pioid -dependant huma	an volunteers'	'; Drug and Alcol	hol Dependenc	e (1990)
	NM								ment of Buprend hool of Medicin	orphine-Naloxone Con e, pp. 145-149.	nbinations"; I	Dept of Psychiatry	and Behavior	al
	NN									and Precipitation of A				on to
EXAMINER										DATE CONSIDERI	ED			
*EXAMINER: I considered. Inc										e with MPEP 609; Dra	w line throug	h citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	IO.:	SERIAL NO.: 10/747,865		
	LIST C	)F PRI	OR A	RT C	ITED I	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	OA	5	5	3	4	4	9	2	7/96	Aston et al.	514	608		
	ОВ	5	5	4	9	9	1_	2	08/27/1996	Oshlack et al.	424	468		
	ос	5	5	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368		
	OD	5	5	5_	6	8	3	8	9/96	Mayer et al.	514	25	_	
	OL	5	5	7	4	0	5	2	11/96	Rose et al.	514	343		
	FOREIGN									OCUMENTS				
	DOCUMENT NUMBER DA									COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
	DOCUMENT NUMBER D.												YES	NO
	OF													
				(	OTHE	R PRIC	OR AR	T (Incl	uding Author, I	itle, Date, Pertinent P	ages, Etc.)			
	OG	Zak	s et al.	, "Nalo	xone 1	reatm	ent of (	Opiate	Dependence"; J	AMA (1971) Vol 215	, No 13, pp. 2	108-2110.		
1	ОН	Bart	on, et	al., "In	tranasa	al Adm	inistra	tion of	Naloxone by Pa	aramdeics";Prehospita	1 Emergency	Care (2002) Vol (	5, No 1, pp. 54	-58.
	OI	Blac	hly, P	aul, H.	, M.D.	, "Nalc	xone i	n Opia	te Addiction"; (	Current Psychiatric Th	erapies (1976	) pp. 209-213.		
	Oì			al., "R (1995)					ontrolled-releas	e oral morphine sulfate	e during naltre	exone blockade";	Inter J of Clin	Pharm
	ок	Jasii 258.		).R., "/	Assessr	nent of	the A	buse P	oteniality of Mo	rphinelike Drugs (Me	thods Used in	Man)"; Drug Ad	diction (1977)	pp. 197-
	OL	Johr	ison et	t al., "E	Bupreno	orphine	e and N	Valoxo	ne for Heroin D	ependence"; Substanc	e Use Disorde	rs (2000) pp. 519	-526.	
	ОМ	Stra 217.		l. <b>,</b> "Opi	ioid an	tagonis	st effec	ts of d	ezocine in opioi	d-dependent humans"	; Clin Pharm	and Thera (1996)	Vol 60, No 2,	, pp. 206-
	ON	Pres 49-8		al., "A	buse li	ability	and st	udies o	f opioid agonist	-antagonists in humar	ns"; Drug and	Alcohol Depende	ence (1991) vo	1 28, pp.
	00									laloxone after Admini sch/Drug Res. (2000)			olution or	
EXAMINER										DATE CONSIDER	ED			
*EXAMINER: considered. Inc										e with MPEP 609; Dra	aw line throug	h citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	IO.:	SERIAL NO.: 10/747,865		
	LIST (	OF PRI	OR A	RT CI	TED I	ЗҮ АР	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	CUME	NT NU	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	PA	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35		
	PB	5_	5	8	0	8	7	6	12/96	Crain et al.	514	282		
	PC	5	5	8	5	3	4	8	12/96	Crain et al.	514	12		
	PD	5	5	9	1	4	5	2	01/04/1997	Miller et al.	424	468		
	PE	5	6	0	1	8	4	5	02/11/1997	Buxton et al.	424	495		
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	NT N	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
													YES	NO
	PF	1												
					ЭТНЕ	R PRIC	R AR	T (Inc	luding Author, T	Title, Date, Pertinent P	ages, Etc.)			
	PG	Ben	fey, "F	unctio	n of M	yocard	ial α-A	Adreno	ceptors"; Life S	Sciences (1982) vol 31	, pp. 101-112			
	PH	Lev	ine et a	al., "Po	tentiat	ion of	Pentaz	ocine A	Analgesia by Lo	w-dose Naloxone"; J	of Clin Invest.	(1988) Vol 82, p	p. 1547-1577.	
	PI			al., "O 994), '					Receptor Upreg	ulation: Effects of Con	ncurrent Agor	ist Administratio	n"; Brain Rese	earch
	РJ								sue Distribution rs (1994) pp. 28	of a Putative Member 4-288.	of the Rat Op	oioid Receptor Ge	ne Family that	is not a
	PK			et al., ' ), pp. 3		l, a no	velmei	nber o	f the opioid rece	eptor family: Cloning,	functional exp	oression and local	ization"; FEB	S letters
	PL	War 75-7		ıl., "cD	NA clo	ning a	=of an	orpha	n opiate recepto	r gene family member	and its splice	variant"; FEBS	etters 348 (19	94) pp.
	PM								preference after 119-131.	chronic treatment wit	h naloxone in	the rat"; Researc	h Communica	tions in
EXAMINER										DATE CONSIDER	ED			
*EXAMINER:										e with MPEP 609; Dra	aw line throug	h citation if not i	n conformance	and not

			_		_	_								
FORM PTO-14 (REV. 7-80)	DOCUMENT NUMBER   DOCUMENT NUMBER   QA   5   6   1   4   6   6   1   4   4   6   6   1   4   4   6   6   1   4   4   6   6   1   4   4   4   4   4   4   4   4   4									ATTY. DOCKET I 200.1134CON	NO.:	SERIAL NO.: 10/747,865		
	LIST (	OF PR	IOR A	RT C	ITED !	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAG	CK et al.			
	(U	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: December 29, 2003	3	GROUP: 1614		
			~					U.S.	PATENT DOC	UMENTS		· · ·		
*EXAMINER INITIAL		DO	CUME	ENT N	UMBÉ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	QA	5	6		4	6	ď	1	4/97	Khanna et al.	514	399		
	QB	5	4	2	2	7	2	2	04/22/1997	Knott et al.	424	494		
	QC	5	6	2	4_	9	3	2	4/97	Qin et al.	514	282		
	QD	5	6	3	3	2	5	9	5/97	Qin et al.	514	282		
	QE	5	6	3	9	4	7	6	06/17/1997	Oshlack et al.	424	468	_	
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	ENT NI	ИМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	QF												:	
					OTHE	R PRIC	OR AR	T (Inc	luding Author, T	Title, Date, Pertinent I	ages, Etc.)			
	QG						atent A	pplica	tion to Be Publi	shed on Abuse-Resist	ant Pain Relie	ver Being Develo	ped by Perdue	;
	QI	Parc	onis et	al., "In	crease	d Anal	gesic F	otency	of Mu Agonist	s after Continuous Na	loxone Infusi	on in Rats"; J fo I	harm Exper T	hera
	QI	Yob	urn et	al., "S	uperse	nsitivit					Antagonist Tr	eatment: Relation	ship to Recep	tor
	QI	Cra	in et al	l., "Acu	ite ther	rmal hy	peralg	esia el	icited by low-do	se morphine in norma	al mice is bloc	ked by ultra-low-	dose naltrexon	ie,
	QI	Zha	ng et a	ıl., "Do	wn-Re	gulatio	n of μ	-Opioi	d Receptors in I	Rat and Monkey Dors	al Root Gangl	ion Neurons and	Spinal Cord A	fter
	QI	Abd	lulla et	t al., "A	xotom	ny redu	ces the	effect	of analgesic op		effect of noci	ceptin on dorsal	oot ganglion n	ieurons";
	QM	Di O	Giannu	iario et	al., "O	rphani	n FQ r	educes	morphine-indu	ced dopamine release	in the nucleu	s accumbens: a m	icrodialysis stu	udy in
EXAMINER	•		•			- 1				DATE CONSIDER	ŒD			
	U.S.  INNER  DOCUMENT NUMBER  QA 5 6 1 4 6 6 1 QB 5 4 2 2 7 2 2 QC 5 6 2 4 9 3 2 QD 5 6 3 9 4 7 6  FOREK  DOCUMENT NUMBER   OTHER PRIOR ART (Incl  QG Press Release "International Patent Applicat Pharma"; Auguest 8, 2001.  QI Paronis et al., "Increased Analgesic Potency (1991), 259 (2), pp. 582-589.  QI Yoburn et al., "Supersensitivity to Opioid A Sensitivity"; Pharmacology Bio Beh (1995)  QI Crain et al., "Acute thermal hyperalgesia eli unmasking potent opioid analgesia"; Brain  QI Zhang et al., "Down-Regulation of µ-Opioir Peripheral Axotomy"; Neuroscience (1998)  QI Abdulla et al., "Axotomy reduces the effect J of Neuro Sci (1998) Vol 18, pp 9685-9694  QM Di Giannuario et al., "Orphanin FQ reduces rats"; Neurosci. Lett (1999) Vol 272 pp. 18:									e with MPEP 609; Dr	aw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 1 200.1134CON	NO.:	SERIAL NO.: 10/747,865		
	LIST (	)F PR	IOR A	RT CI	TED I	BY AF	PLIC	ANT		APPLICANT(S): Benjamin OSHLA	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 200	3	GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT NU	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROF	
	RA	5	6	5	6	2	9	5	08/12/1997	Oshalck et al.	424	468		
	RB	5	6	7	0	1	7	2	09/23/1997	Buxton et al.	424	495		
	RC	5	6	7	2	3	6	0	09/30/1997	Sackler et al.	424	490		
	RD	5	6	8	1	5	8	5	10/28/1997	Oshlack et al.	424	494		
	RE	5	7	6	3	4	5	2	06/09/1998	Miller et al.	514	282		
	RF	5	7	6	7	1	2	5	06/98	Crain et al.	514	282		
	RG	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
	RH	5	7	6	7	1	2	5	06/16/1988	Crain, et al.	514	282		
									08/01/2000	Crain, et al.	514	282		
	RJ	6	1	9	4	3	8	2	02/27/01	Crain, et al.	514	2		
	RK	6	3	6	2	1	9	4	03/26/2002	Crain, et al.	514	285		
	RL	6	3	9	5	7	0	5	05/28/2002	Crain, et al.	514	2		
	RM	20	01	00	06	9	6	7	07/05/2001	Crain, et al.	514	253.04		
	RN	20	01	00	18	4	1	3	08/30/2001	Crain, et al.	514	2		
							F	OREI	GN PATENT D	OCUMENTS				
		DOC	CUME	NT NU	JMBE:	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	RO													
			<b>.</b>	(	OTHE	R PRIC	OR AR	T (Incl	uding Author, 7	litle, Date, Pertinent I	Pages, Etc.)			
	RP		cociop <sub>1</sub>	oo et al						ne Rewarding Propert		ne"; Eur. J Pharm	acol (2000) V	ol 404,
	RQ				Refere	ence (2	:001) s	ee Rev	ria, pp. 1146-11	49 and Oxycontin, pp	. 2697-2701			
	RR													
	RS													
EXAMINER										DATE CONSIDER	RED			
*EXAMINER: considered. Inc										e with MPEP 609; Di	raw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	0.:	SERIAL NO.: 10/747,865		
	LIST (	)F PRI	IOR A	RT CI	TED I	ву ар	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003	_	GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	SA	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498		
	SB	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282		
	sc	5	8	4	3	4	8	0	12/01/1998	Miller et al.	424	484		
	SD	5	8	4	9	2	4	0	12/15/1998	Miller et al.	264	460		
	SE	5	8	5	8	0	1	7	1/99	Demopulos et al.	604	890.1		
	SF	5	8	6	0	9	5	0	1/99	Demopulos et al.	604	49		
	SG	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472		
	SH	5	4	0	9	9	4	4	04/25/1995	Black et al.	514	359		
	SI	5	1	3	0	3	1	1	07/14/1992	Guillaumet et al.	514	234.2		
	SJ	4	4	0	1	6	7	2	08/30/1983	Portoghese	424	260		
	SK	4	4	5	7	9	3	3	07/03/1984	Gordon et al.	424	260		
	SL	5	4	3	6	7	6	5	07/25/1995	Black et al.	514	420		
	SM	5	6	3	9	7	8	0	06/17/1997	Lau et al.	514	419		
	SN	5	6	0	4	2	6	0	02/18/1997	Guay et al.	514	605		
	so	5	6	0	4	2	5	3	02/18/1997	Lau et al.	514	415		
	SP	5	5	9	3	9	9	4	01/14/1997	Batt et al.	514	252		
	SQ	5	5	3	6	7	5	2	07/16/1996	Ducharme et al.	514	602		
	SR	5	5	5	0	1	4	2	08/27/1996	Ducharme et al.	514	365		
	SS	5	5	7	1	2	1	3	05/28/1996	Prasit et al.	514	443		
	ST	5	5	1	0	3	6	8	04/23/1996	Lau et al.	514	419		
	SU	5	4_	7	4	3	5	5_	12/12/1995	Ducharme et al.	514	241		
							F	OREI	GN PATENT D	OCUMENTS				_
		DO	CUME	ENT N	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	sx													
					ЭТНЕ	R PRIO	OR AR	T (Inc	luding Author,	Title, Date, Pertinent Pa	ages, Etc.)			
	SY													
EXAMINER										DATE CONSIDERI	ED			
*EXAMINER: considered. Inc										l e with MPEP 609; Dra	w line throug	h citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									ATTY. DOCKET N 200.1134CON	O.:	SERIAL NO.: 10/747,865		
	LIST (	OF PR	IOR A	RT CI	TED 1	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	(U	se seve	ral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROF	
	TA	5	8	6	9	0	9	7	02/09/1999	Wong et al.	424	473		
	ТВ	5	8	7	9	7	0	5	03/09/1999	Heafield et al.	424	464		
	TC	5	8	8	0	1	3	2	3/99	Hill	514	282		
	TD _	5	8	9	1	4	7	ı	04/06/1999	Miller et al.	424	468		
	TE	5	9	0	8	8	4	8	06/01/1999	Miller et al.	514	282		
	TF	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426		
	TG	5	9	5_	8	4	5	2	09/28/1999	Oshlack et al.	424	457		
	тн	3	8	4	5	7	7	0	11/05/1974	Theeuwes et al.	128	260		
	TI	4	0	6	3	0	6	4	12/13/1977	Saunders et al.	219	121	ļ <u>.</u>	
	TJ	4	0	8	8	8	6	4	05/09/1978	Theeuwes et al.	219	121		
	тк	4	2	9	3	5	3	9	10/06/1981	Ludwig et al.	429	19		
	TL	4	9	5	7	6	8	1	09/18/1990	Klimesch et al.	264	211.23		
							F	OREI	GN PATENT D	OCUMENTS			· · · · · · · · · · · · · · · · · · ·	
	4	DO	CUME	NT NU	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
				<b>.</b>	·								YES	NO
	TM					<u> </u>							<u> </u>	
				(	ЭТНЕ	R PRIC	R AR	T (Incl	uding Author, T	itle, Date, Pertinent Pa	ages, Etc.)			
	TN													
	то									-				
	TP													
	TQ												<u>.</u> .	
	TR													
	TS									_				
EXAMINER										DATE CONSIDERI	ED			
	TA 5 8 6 9 0 9 7 02/0  TB 5 8 7 9 7 0 5 03/0  TC 5 8 8 8 0 1 3 2 3/99  TD 5 8 9 1 4 7 1 04/0  TE 5 9 0 8 8 4 8 06/0  TF 5 9 4 2 2 4 1 8/99  TG 5 9 5 8 4 5 2 09/2  TH 3 8 4 5 7 7 0 11/0  TI 4 0 6 3 0 6 4 12/0  TJ 4 0 8 8 8 8 6 4 05/0  TK 4 2 9 3 5 3 9 10/0  TL 4 9 5 7 6 8 1 09/0  FOREIGN PA  DOCUMENT NUMBER   OTHER PRIOR ART (Including TR)  TO TP  TQ  TR  TG  TR  TG  TR  TG  TR									e with MPEP 609; Dra	w line throug	h citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	U.S. PATENT AND TRADEMARK  LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)  U.S. PATENT AND TRADEMARK  (Use several sheets if necessary)  U.S. PATENT AND TRADEMARK  U.S. PATENT AND TRADE									ATTY. DOCKET 200.1134CON	NO.:	SERIAL NO.: 10/747,865		
	LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)  U.S. PATE  MININER AL  UA 5 9 5 8 4 5 9 09/2  UB 5 9 6 5 1 6 1 10/2  UC 5 9 6 5 1 6 3 10/2  UD 5 9 6 8 5 4 7 10/2  UE 5 9 6 8 5 5 1 10/2  UF 5 9 7 2 9 5 4 10/2  UF 5 9 7 2 9 5 4 10/2  UH 3 1 7 3 8 7 7 03/2  UH 3 1 7 3 8 7 7 03/2  UI 4 5 8 7 1 1 8 05/2  FOREIGN PATE  DOCUMENT NUMBER  DAY  DOCUMENT NUMBER  DAY									APPLICANT(S): Benjamin OSHLA	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: December 29, 200	3	GROUP: 1614		
		_						U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	UA	5	9	5	88	4	5	9	09/28/1999	Chasin et al.	424	490		
	UB	5_	9	6	5	1	6_	1	10/12/1999	Oshlack et al.	424	457		
	UC	5_	9	6	5	1	6	3	10/12/1999	Miller et al.	424	468		
_	UD	5_	9	6	8	5	4_	7	10/99	Reder et al.	424	449		
										Oshlack et al.	424	456		
	UF 5 9 7 2 9 5 4 10/99									Foss	514	282		
										Mitch et al.	514	210.16		
	UH	3	1	7	3	8	7	7	03/16/1965	Jackson et al.	252	138		
	UI	4_	5	8	7	1	1_1_	8	05/06/1986	Hsiao	424	459	,	
							F	OREI	GN PATENT D	OCUMENTS		<b>,</b>	· · · · · · · · · · · · · · · · · · ·	
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
													YES	NO
	UJ	04	0	5	2	3	4	6	06/24/2004	WO(A1)	A61K	9/62		
	UK	0	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
	UL	9	9	1	3	7	9	9	03/25/1999	WO (A1)	A61F	2/02		
		<del>,</del> .		(	ОТНЕ	R PRIC	OR AR	T (Incl	uding Author, T	Title, Date, Pertinent	Pages, Etc.)			
	UM													
	UN	ļ												
	υo													
	UP										<del></del> -			
	UQ	<u> </u>												
	UR													
	US													
EXAMINER										DATE CONSIDER	RED			
*EXAMINER: considered. Inc										e with MPEP 609; Di	raw line throug	gh citation if not i	n conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	Ю.:	SERIAL NO.: 10/747,865		
	LIST	OF PR	IOR A	RT C	ITED :	BY AI	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(U	se seve	eral she	ets if r	necessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DO	CUMI	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	VA	6	0	2	4	9	8	2	02/15/2000	Oshlack et al.	424	476		
	VB	6	0	6	8	8	5	5	05/30/2000	Leslie et al.	424	468		
	VC	6	0	7	7	5	3	2	06/20/2000	Malkowska et al.	424	457		
	VD	6	0	7	7	5	3	3	06/20/2000	Oshlack et al.	424	461		
	VE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
	VF	6	1	0	3	2	6	1	08/15/2000	Chasin et al.	424	459		
	VG	6	1	4_	3	3	2	2	11/07/2000	Sackler et al	424	459		
							F	OREI	GN PATENT D	OCUMENTS				
		DO	CUME	ENT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	VH													
	VI													
	VJ													
	VK													
	VL													
	_				ОТНЕ	R PRIC	OR AR	T (Incl	uding Author,	Fitle, Date, Pertinent P	ages, Etc.)			
	VM									-				
	VN										-			
	vo													
	VP						·					,		
	VQ													
	VR													
	vs				_									
EXAMINER										DATE CONSIDER	ED			
*EXAMINER:										e with MPEP 609; Dra	w line throug	th citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	10.:	SERIAL NO.: 10/747,865		
	LIST C	)F PRI	OR A	RT C	TED 1	ВҮ АР	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			
	(Us	se seve	ral she	ets if n	ecessa	гу)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOG	CUME	ENT NU	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	WA	6	1	4	3	3	2	8	11/07/2000	Heafield et al.	424	489		
	WB	6	1	6	2	4	6	7	12/19/2000	Miller et al.	424	468		
	wc	6	2	1	0	7	1	4	04/03/2001	Oshlack et al.	424	476		
1	WD	6	2	2	8	8	6	3	05/08/2001	Palermo et al.	514	282		
Ĭ	WE	6	2	5	4	8	8	7	07/03/2001	Miller et al.	424	468		
	WF 6 2 6 1 5 9 9 07/									Oshlack et al.	424	457		
	WG 6 2 7 7 3 8 4 08/2									Kaiko et al.	424	400		
							1	OREI	GN P/TENT DO	OCUMENTS				
		DOG	CUME	NT NU	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	WH													
	wı													
	WE													
	WK													
	WL													
					ЭТНЕ	R PRIC	R AR	T (Incl	uding Author, 7	Γitle, Date, Pertinent P	ages, Etc.)			
	WM													
	WN													
	wo													
	WP													
	WQ													
	WR													
	ws													
EXAMINER										DATE CONSIDER	ED			
*EXAMINER: considered. Inc	Initial if i	eferen	ce cons	sidered with r	l, whet	her or i	not cita	ation is to app	in conformanc	e with MPEP 609; Dra	aw line throug	h citation if not in	n conformance	and not

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623			
LIST OF PRIOR ART CITED BY APPLICANT										APPLICANT(S): Benjamin OSHLACK et al.					
(Use several sheets if necessary)										FILING DATE: December 29, 2003		GROUP: 1614			
								U.S.	PATENT DOC	CUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER DATE								NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	XA	6	2	9	4	1	9	5_	09/25/2001	Oshlack et al.	424	457			
	XB	6	3	0	6	4	3	8	10/23/2001	Oshlack et al.	424	468			
	хc	6	3	2	6	0	2	7	12/04/2001	Miller et al.	424	468			
	XD	6	3	3	5	0	3	3	01/01/2002	Oshlack et al.	424	457			
	XE	6	3	7	5	9	5	7	04/23/2002	Kaiko et al.	424	400			
	XF	6	3	8	7	4	0	4	05/14/2002	Oshlack et al.	424	480			
	XG	6	3	9	9	0	9	6	06/04/2002	Miller et al.	424	464			
	хн	6	4	7	5	4	9	4	11/05/2002	Kaiko et al.	424	400			
	ΧI	6	6	2	7	6	3	5	09/30/2003	Palermo, et al.	514	282			
	XJ	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449			
	XK	6	6	9	6	0	8	8	02/24/2004	Oshlack et al.	424	465			
	XL	6	6	9	6	0	6	6	02/24/2004	Kaiko et al.	424	400			
FOREIGN PAT	ENT DO	CUME	ENTS										-		
	DOCUMENT NUMBER DATE								COUNTRY	CLASS	SUBCLASS	TRANSLATION			
													YES	NO	
	ХМ														
				1 (	OTHE	R PRIC	)R AR	T (Inc	luding Author.	Title, Date, Pertinent	Pages, Etc.)	1			
	XN		-					(	,	,					
	хо		-												
	XP										· · · ·	-			
<del></del>	XQ	1													
	XR														
	XS					-									
	XT														
EXAMINER										DATE CONSIDERED					
*EXAMINER: considered. Inc										e with MPEP 609; D	raw line throu	gh citation if not i	n conformanc	e and not	